Minor
atorvastatin × clopidogrel
HMG-CoA reductase inhibitors (statins)×Antiplatelet agents – P2Y12 receptor inhibitors
Mechanism
An early study by Lau et al. (Circulation, 2003) in 44 patients showed in vitro that atorvastatin competes with clopidogrel for CYP3A4 and blunts the aggregation response. Subsequent large-scale clinical data did not confirm the hypothesis. Analysis of more than 13,000 patients from CHARISMA (Saw et al., 2007) found no difference in cardiovascular events on DAPT between CYP3A4-metabolized statins and other statins. A systematic review by Hicks et al. (BMJ, 2010) and a meta-analysis by Mukherjee et al. (Arch Intern Med, 2008) reached the same conclusion. The FDA, EMA, and ESC have issued no warnings about this pair.
Management
No statin change is needed. Per ESC ACS 2023 and AHA/ACC 2018 Cholesterol Guidelines, all post-ACS patients should receive high-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) regardless of the P2Y12 inhibitor chosen. In most DAPT patients atorvastatin remains the preferred statin.
Sources
- CHARISMA Investigators: Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial (2007)— Circulation 2003;108(8):921–924; CHARISMA substudy: Am Heart J 2007;153(5):806.e1–6
- BMJ: Concurrent use of statins and clopidogrel after percutaneous coronary intervention: meta-analysis (2010)— BMJ 2010;340:c2143 (Hicks BM et al.)
- Archives of Internal Medicine: Lack of effect of statins on clopidogrel: a meta-analysis (2008)— Arch Intern Med 2008;168(16):1843–1846 (Mukherjee D et al.)
- ESC: 2023 ESC Guidelines for the management of acute coronary syndromes (2023)— Eur Heart J 2023;44(38):3720–3826
- ACC/AHA: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018)— Circulation 2019;139(25):e1082–e1143